One of Wales' leading life sciences firms, Creo Medical, said that revenues in the first half of its financial year are expected to come in more than 10% higher (around £13.5m) than the second half of 2021, following strong trading.
The Chepstow-based Alternative Investment Market listed firm, which is focused on the emerging field of surgical endoscopy, said that growth has been driven from its core technology, including first revenues from it Kamaptive licensing programme
. Increases in revenue and gross margins, coupled with a reduction in underlying operating costs, also means it expects to report a reduction of over 20% in underlying Ebitda loss the first half of this year compared to 2021. It has also seen an increase number of clinicians able to provide training on Creo’s technology has doubled compared to the previous six months.
